8-KThe WireRoutine
Shareholder Vote
Filed May 5, 2023 · 3y ago · Accession 0001193125-23-137079
Plain English
Material event — a significant development the company must disclose promptly.
Read the source below for the full document.
Filing text
View original ↗UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2023
MODERNA, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38753
81-3467528
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
200 Technology Square
Cambridge , MA
02139
(Address of principal executive offices)
(Zip code)
Registrant’s telephone number, including area code: (617) 714-6500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
symbol(s)
Name of each exchange
on which registered
Common stock, par value $0.0001 per share
MRNA
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07
Submission of Matters to a Vote of Security Holders.
On May 3, 2023, Moderna, Inc. (the “Company”) held its previously announced 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. The final voting results for the Annual Meeting are as follows:
Proposal 1. Election of directors.
By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as Class II directors for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal:
For
Withheld
Broker
Non-Votes
Stephen Berenson
226,559,326
64,151,669
29,473,257
Sandra Horning, M.D.
281,767,010
8,943,985
29,473,257
Paul Sagan
219,030,508
71,680,487
29,473,257
Proposal 2. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers.
The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers. The results of the stockholders’ vote with respect to the approval of the compensation of the named executive officers were as follows:
Votes For
Votes Against
Abstain
254,146,335
34,946,612
1,618,048
There were 29,473,257 broker non-votes on the proposal.
Proposal 3. Ratification of appointment of independent registered public accounting firm.
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, with the votes cast as follows:
Votes For
Votes Against
Abstain
351,997,808
3,947,914
238,530
Proposal 4. Shareholder proposal requesting a report on feasibility of transferring intellectual property.
Votes For
Votes Against
Abstain
21,423,446
267,992,196
1,295,353
There were 29,473,257 broker non-votes on the proposal.
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 5, 2023
MODERNA, INC.
By:
/s/ Shannon Thyme Klinger
Shannon Thyme Klinger
Chief Legal Officer and Corporate Secretary
Filing details
- Company
- Moderna, Inc.
- Ticker
- MRNA
- CIK
- 1682852
- Form type
- 8-K
- Filing date
- May 5, 2023
- Report date
- May 3, 2023
- Document
- d415922d8k.htm
- Size
- 149 KB